Copper(II) glycyl-L-histidyl-L-lysine (GHK-Cu)
copper peptide, copper tripeptide-1, Cu-GHK, GHK, GHK-copper complex, GHK-Cu, glycyl-L-histidyl-L-lysine copper, glycyl-L-histidyl-L-lysine copper(II), prezatide copper, tripeptide-1 copper
Copper tripeptide-1 is a naturally occurring human plasma tripeptide, glycyl-histidyl-lysine, bound to copper(II). It has the strongest biological pedigree in the cosmetic peptide category, with a real wound-healing trial and a large mechanistic literature. It is also the compound where the gap between mechanistic enthusiasm and rigorous cosmetic evidence is widest, and where much of the advocacy literature is written by the person who commercialised it.
Mechanism
GHK was isolated from human plasma albumin fraction by Loren Pickart in 1973. Its defining property is high-affinity chelation of copper(II). The histidine imidazole, the N-terminal amine and the deprotonated peptide nitrogen form a coordination site that binds Cu(II) tightly enough to extract it from albumin, yet loosely enough to hand it on to cells. The complex therefore functions as a physiological copper shuttle rather than as a conventional receptor ligand.
Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibrils, and for superoxide dismutase and cytochrome c oxidase. Delivering copper into fibroblasts plausibly supports matrix assembly directly. Beyond copper delivery, GHK-Cu has been reported to stimulate both synthesis and breakdown of collagen and glycosaminoglycans, to modulate matrix metalloproteinases and their inhibitors, to stimulate decorin, to restore replicative vitality to irradiated fibroblasts, to attract immune and endothelial cells to injury sites, and to promote wound healing across several tissues in several species. Gene-expression work by Pickart and Margolina reports that GHK is capable of up- and downregulating at least 4,000 human genes.
Two caveats belong with that list. First, breadth of reported activity is not the same as demonstrated therapeutic effect; a molecule reported to influence thousands of genes in a transcriptomic screen is a molecule whose specific mechanism has not been pinned down. Second, the great majority of the gene-expression and mechanistic review literature is authored by the peptide's commercial developer, writing from the address of his own company. This does not make it wrong, but it means the mechanistic case has not been independently stress-tested to the degree the volume of publication might suggest.
What the research shows
The strongest human data is not cosmetic at all. Mulder and colleagues (1994) ran a multicentre, randomised, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel in diabetic neuropathic ulcers, with all patients on an aggressive standardised protocol of sharp debridement, pressure-relieving footwear and diabetes education. Median area percentage closure of plantar ulcers was 98.5% with GHK-Cu versus 60.8% for vehicle (p < 0.05); the rate of closure was three times faster; in ulcers larger than 100 square millimetres the difference was starker still (89.2% versus -10.3%, p < 0.01); and ulcer infection incidence was 7% versus 34% (p < 0.05). That is a substantial result on a hard clinical endpoint. It is also over thirty years old, was never followed by a confirmatory trial, and did not lead to an approved product, which is itself informative.
The best-controlled dermatological trial found no between-group difference. Miller and colleagues (2006) randomised patients undergoing circumoral CO2 laser resurfacing to post-treatment skincare regimens with or without copper tripeptide complex, with blinded computer-assisted erythema assessment over 12 weeks; 13 patients completed. There was no statistically significant difference between groups for earlier resolution of erythema. All patients experienced significant improvement in wrinkles and overall skin quality after resurfacing, but no difference was found between the groups. That is, the laser worked and the peptide added nothing measurable. The only endpoint favouring GHK-Cu was the patient questionnaire, which showed significantly greater self-reported improvement in overall skin quality (P = .04). A dissociation between what patients report and what blinded objective measurement finds deserves to be stated plainly rather than buried.
The study that anchors most consumer confidence in topical GHK-Cu (Leyden and colleagues, 2002, reporting increased skin density and reduced fine lines in 71 women with photoaged skin after 12 weeks) is cited everywhere as an American Academy of Dermatology meeting abstract. We could not locate it in PubMed or any other indexed database during this audit, and no PMID or DOI exists for it. Meeting abstracts are not peer-reviewed in any meaningful sense, contain no methods section a reader can evaluate, and frequently never reach full publication. Citing it as a clinical trial, as much of the internet does, misrepresents what it is.
So the honest position is: GHK-Cu is a genuine endogenous human molecule with well-characterised chemistry, one strong old wound-healing RCT, one properly published dermatological RCT that found no objective between-group benefit, a large preclinical and transcriptomic literature dominated by its commercial developer, and no properly published, independently conducted, randomised controlled trial demonstrating anti-ageing benefit on human facial skin.
Evidence assessment
Mixed evidence
A multicentre randomised evaluator-blinded trial in diabetic ulcers reported a large healing benefit, but the best-controlled dermatological trial found no between-group difference on objective endpoints, and the widely cited facial cream studies are unindexed conference abstracts.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Limited evidence
No significant between-group difference in resolution of post-treatment erythema and no significant objective improvement in wrinkles or overall skin quality; only the patient questionnaire measure of overall skin quality favoured GHK-Cu (P=0.04).
Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ Preclinical only
The copper complex increased synthesis of sulphated glycosaminoglycans, a core matrix component of repairing tissue.
Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts Preclinical only
Tripeptide-copper complexes accelerated wound healing and affected fibroblast behaviour in culture.
Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy Preclinical only
Characterises limited penetration of the copper tripeptide through the stratum corneum, with most material retained in the upper layers.
The human tri-peptide GHK and tissue remodeling Preclinical only
Summarises the proposed role of GHK-Cu in wound healing and matrix remodelling across multiple model systems.
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health Preclinical only
Proposes GHK as a candidate agent against age-associated neurodegeneration on the basis of gene-expression and antioxidant data.
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper Mixed evidence
Median area percentage closure of plantar ulcers was 98.5% with GHK-Cu versus 60.8% for vehicle (p<0.05), closure was three times faster, the effect was larger in ulcers over 100 mm2 (89.2% versus -10.3%, p<0.01), and ulcer infection incidence was 7% versus 34% (p<0.05).
Skin care benefits of copper peptide containing facial cream (and companion eye cream study) Limited evidence
Reported increases in skin density and thickness and reductions in fine lines and laxity versus control.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration Preclinical only
Reviews reported effects on collagen, glycosaminoglycan and proteoglycan synthesis, metalloproteinase modulation, fibroblast vitality after irradiation, and wound healing across multiple tissues and species, and states that GHK is capable of up- and downregulating at least 4,000 human genes.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Preclinical only
Reports effects on vessel and nerve outgrowth, matrix synthesis, tissue repair across several organs, anti-inflammatory and anti-cancer activity, DNA repair and proteasome activation, and argues that recent genetic data explains this breadth.
Safety
Topically, GHK-Cu has been used in cosmetics for decades without a significant safety signal; irritation is uncommon and typically vehicle-related. Two concerns are worth stating. The first is copper itself: the therapeutic argument depends on delivering copper into tissue, and copper is a redox-active metal that in excess drives Fenton chemistry and oxidative damage. Topical cosmetic doses are small, but the same reasoning does not automatically extend to repeated injection. The second is regulatory. Injectable copper peptide has been nominated as a bulk drug substance for use in 503A compounding in the United States, and it has been reported as placed in FDA's Category 2 (the category for substances where the agency identified significant safety risks), which would restrict compounding. We were not able to re-verify that listing against FDA's own current published list during this audit, and the list has been revised more than once, so treat this as an unconfirmed report and consult the current FDA 503A bulk drug substances list directly rather than any secondary summary, including this one. What is not in dispute: there is no adequate human safety database for injected or systemically administered GHK-Cu, and material sold in vials labelled 'for research use only' has no verified sterility, purity or copper stoichiometry.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation for topical use with cosmetic claims only. No MHRA marketing authorisation for any medicinal indication. Injectable preparations are unlicensed medicines and cannot lawfully be supplied for human use. |
| United States | Not an FDA-approved drug for any indication. Permitted as a topical cosmetic ingredient, where claims must remain cosmetic rather than therapeutic. Injectable GHK-Cu was among the peptides placed on the FDA's interim 503A Category 2 compounding list in September 2023; that list was subsequently revised following nomination withdrawals and peptide nominations were referred to the Pharmacy Compounding Advisory Committee. |
| WADA (sport) | Not individually named on the Prohibited List. Athletes should note that the S2.3 clause covering growth factors and growth factor modulators affecting vascularisation and regenerative capacity is written broadly, and should seek guidance from their anti-doping organisation before using any injected regenerative peptide. |
Questions
The honest answer is that the best-controlled trial says not measurably. In a randomised study of patients after CO2 laser resurfacing, blinded evaluators and computer analysis found no significant between-group improvement in erythema, wrinkles or skin quality with GHK-Cu. Patients using it reported feeling their skin was better. That gap between measured and reported outcomes is exactly the pattern you would expect from an ingredient with a real but small or absent effect.
Nobody knows, and the topical safety record does not answer the question. There are no published human pharmacokinetics, no dosimetry and no repeat-dose toxicology for injected GHK-Cu. Injection introduces a copper chelate systemically, and copper overload has established hepatic and neurological toxicity. This is one of the few peptides in the class where the delivery route changes the risk profile fundamentally.
Because the intact complex penetrates skin poorly. GHK-Cu is charged and hydrophilic, and human skin penetration studies show most of it is retained in the upper stratum corneum rather than reaching living dermis where fibroblasts are. Liposomal encapsulation and lipidation (as in palmitoyl tripeptide-1) are both attempts to solve this delivery problem, which tells you the problem is real.
No. GHK is the free tripeptide glycyl-histidyl-lysine. GHK-Cu is its 1:1 complex with copper(II), and most of the proposed biological activity is attributed to the complex rather than the bare peptide, because copper is what supplies the cofactor for lysyl oxidase and superoxide dismutase. Products differ in whether and how much copper they actually contain.
Not from a properly published randomised trial. The study everyone cites (Leyden 2002, 71 women, 12 weeks) is a conference abstract we could not locate in any indexed database. The one well-controlled dermatological RCT that was properly published (Miller 2006, post-laser skin) found no difference between the GHK-Cu and control regimens on erythema, wrinkles or skin quality; only the patient questionnaire favoured it. The strong human data for GHK-Cu is in diabetic ulcer healing, not facial ageing.
Yes, genuinely. GHK is a normal constituent of human plasma, first isolated from albumin fraction in 1973, and plasma levels are reported to decline with age. That is an unusually solid biological starting point compared with most cosmetic peptides. It does not by itself establish that applying more of it to the skin produces a clinical benefit.
Injectable copper peptide has been nominated as a bulk drug substance for 503A compounding in the United States, and has been reported as placed in the category for substances where FDA identified significant safety risks, which would restrict compounding pharmacies from using it. We could not re-verify that listing against FDA's current published list during this review, and the list has been revised, so check the FDA source directly. Any such concerns related to the injectable route, not to topical cosmetic use.
This is a formulation question rather than an evidence question, and the honest answer is that the concern is theoretical. Copper is redox-active and ascorbic acid is a reducing agent, so a direct chemical interaction is chemically plausible, and low pH can affect the chelate. There are no published clinical data on whether layering them reduces the effect of either in practice.